Article Abstract

Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer

Authors: Fernando Franco, David Pérez-Callejo, Mariano Provencio

Abstract

At the time of diagnosis, 30% of patients with small cell lung carcinoma (SCLC) present a limited stage of disease, which is now called I-IIIB (IASLC). However, the outcome of limited-stage SCLC remains poor, with a median survival of 16 to 24 months using current treatments, and only 15–25% of long-term survivors.